Skip to main content
An official website of the United States government

alpelisib

View Patient Information
An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:phosphoinositide 3-kinase inhibitor BYL719
US brand name:Piqray
Vijoice
Code name:BYL 719
BYL-719
BYL719
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search